**Novogen 30 second overview**

Novogen owns two proprietary drug technology platforms that are first-in-class and which the Company believes will be the foundation that will enable it to grow into a major global bio-pharmaceutical force.

Both technologies target essential functions that lie at the heart of cells behaving abnormally. These essential functions are present across a wide range of degenerative diseases including cancer, neurodegenerative disorders and autoimmune diseases.

These are entirely novel drug targets and Novogen believes exploiting them will revolutionize the treatment of many of the common diseases affecting our community and for which no curative treatments currently exist.

The first of our technologies is a family of small molecules known as super- benzopyrans (SBPs). SBPs regulate the function of tissue stem cells, the first molecules ever found to do so.

Our primary focus is the development of a family of SBP drugs whose principal feature is their ability to kill both cancer stem cells and their daughter cells. In so doing, we hope to be able successfully in a world-first to prevent recurrence of malignant cancers.

The second technology is our anti-tropomyosin (ATM) technology. This targets the micro-filament component of a cancer cell's cytoskeleton. The molecular target of this new class of drug is a specific isoform of tropomyosin that is a key structural protein commandeered by cancer cells. The primary indication of this technology is its potent ability to synergize the anti-cancer effect of taxanes and vinca alkaloids that also target the cytoskeleton.

Novogen has a pipeline of 4 oncology candidates that currently are pre-clinical but are scheduled to enter first-in-man studies across a wide of cancers commencing 4Q15.